Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study
American Journal of Psychiatry · 2025-12 · 182 (12) · 1060-1071
DOI: 10.1176/appi.ajp.20241127 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Psychiatry, 2025-12. Verfasst von Chih-Wan Grace Lin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Methadone, Buprenorphine, Opioid-Related Disorders, Opiate Substitution Treatment. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
OBJECTIVE: Treatment of pregnant patients with opioid use disorder with methadone or buprenorphine is crucial for maternal and neonatal safety. While several clinical trials have demonstrated higher treatment discontinuation rates for buprenorphine compared with methadone outside of pregnancy, evidence during pregnancy and the postpartum period is limited. The authors compared treatment discontinuation between buprenorphine and methadone during pregnancy and over follow-up through 1 year postpartum. METHODS: This was a cohort study, using nationwide Medicaid data, of pregnant patients who initiated methadone or transmucosal buprenorphine (with or without naloxone) for opioid use disorder during the first trimester. The primary outcome was treatment discontinuation, defined as a treatment gap ≥60 days; alternative definitions for discontinuation were explored in sensitivity analyses. Hazard ratios were estimated using Cox proportional hazards regression with propensity score overlap weighting to control for confounding. Subgroup analyses were conducted, stratified by buprenorphine alone versus the buprenorphine/naloxone combination, each compared to methadone. RESULTS: Overall, 696 pregnant patients were identified who initiated methadone treatment and 1,538 who initiated buprenorphine treatment in the first trimester. Compared to methadone initiators, buprenorphine initiators were more likely to discontinue treatment during pregnancy (32.8% for buprenorphine vs. 25.6% for methadone; weighted hazard ratio=1.41, 95% CI=1.15, 1.72) and through 1 year postpartum (58.8% vs. 49.0%; hazard ratio=1.37, 95% CI=1.19, 1.57). For patients initiating the buprenorphine/naloxone combination, the hazard ratio was 1.73 (95% CI=1.36, 2.19) during pregnancy and 1.56 (95% CI=1.30, 1.86) through 1 year postpartum. For patients initiating buprenorphine alone, the hazard ratios were 1.14 (95% CI=0.90, 1.46) and 1.23 (95% CI=1.04, 1.46), respectively. Varying the treatment gap used to define discontinuation in sensitivity analyses yielded consistent results. CONCLUSION: Pregnant patients initiating transmucosal buprenorphine during early pregnancy were more likely to discontinue treatment than those initiating methadone, but treatment discontinuation was high for both treatments. The study findings highlight the importance of identifying and addressing barriers to treatment retention among pregnant patients with opioid use disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston.
- UNC Horizons and Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill.
- Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, MA.
- Department of Psychiatry, Harvard Medical School, Boston.
Förderung
- NIDA NIH HHS
- NICHD NIH HHS
Zitieren
APA
Lin, C. W. G., Bateman, B. T., Straub, L., Hernández-Díaz, S., Vine, S. M., Jones, H. E., Connery, H. S., Davis, J. M., Gray, K. J., Lester, B., Suarez, E. A., Sujan, A. C., Terplan, M., & Huybrechts, K. F. (2025). Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study. American Journal of Psychiatry, 182(12), 1060-1071. https://doi.org/10.1176/appi.ajp.20241127
Vancouver
Lin CWG, Bateman BT, Straub L, Hernández-Díaz S, Vine SM, Jones HE, et al. Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study. American Journal of Psychiatry. 2025;182(12):1060-1071. doi:10.1176/appi.ajp.20241127
BibTeX
@article{Lin2025,
author = {Lin, Chih-Wan Grace and Bateman, Brian T and Straub, Loreen and Hernández-Díaz, Sonia and Vine, Seanna M and Jones, Hendrée E and Connery, Hilary S and Davis, Jonathan M and Gray, Kathryn J and Lester, Barry and Suarez, Elizabeth A and Sujan, Ayesha C and Terplan, Mishka and Huybrechts, Krista F},
title = {Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study},
journal = {American Journal of Psychiatry},
year = {2025},
volume = {182},
number = {12},
pages = {1060--1071},
doi = {10.1176/appi.ajp.20241127}
}
EUVIMED